{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:12:17Z","timestamp":1789517537354,"version":"build-2803163510"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,12,22]],"date-time":"2008-12-22T00:00:00Z","timestamp":1229904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:\u2002<\/jats:bold>\n                    Bilastine is a novel, nonsedating H\n                    <jats:sub>1<\/jats:sub>\n                    \u2010antihistamine developed for symptomatic treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria. The objective of this study was to compare the efficacy and safety of bilastine 20\u2003mg\n                    <jats:italic>vs<\/jats:italic>\n                    placebo and desloratadine 5\u2003mg in subjects with seasonal allergic rhinitis (SAR).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    This randomized, double blind, placebo\u2010controlled, parallel\u2010group multicentre study evaluated the effect of 2\u2003weeks\u2019 treatment with bilastine 20 mg, desloratadine 5\u2003mg or matched placebo once daily, in 12\u201370\u2003years old symptomatic SAR patients. All subjects assessed the severity of nasal (obstruction, rhinorrhoea, itching, and sneezing) and nonnasal (ocular itching, tearing, ocular redness, itching of ears and\/or palate) symptoms on a predetermined scale to provide a total symptom score (TSS), composed of nasal and nonnasal symptom scores (NSS and NNSS, respectively). The primary efficacy measure was the area under the curve (AUC) for the TSS over the entire treatment period.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    Bilastine 20\u2003mg significantly reduced the AUC of TSS to a greater degree from baseline compared to placebo (98.4 with bilastine\n                    <jats:italic>vs<\/jats:italic>\n                    118.4 with placebo;\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u20030.001), but not compared to desloratadine 5\u2003mg (100.5). Bilastine 20\u2003mg was not different from desloratadine 5\u2003mg but significantly more effective than placebo in improving the NSS, NNSS, and rhinitis\u2010associated discomfort scores (\n                    <jats:italic>P\u2003&lt;\u2003<\/jats:italic>\n                    0.05), and rhinoconjunctivitis quality of life questionnaire total (\n                    <jats:italic>P\u2003&lt;\u2003<\/jats:italic>\n                    0.005) and four out of seven individual domain (\n                    <jats:italic>P\u2003&lt;\u2003<\/jats:italic>\n                    0.05) scores. The incidence of treatment emergent adverse events was similar for bilastine (20.6%), desloratadine (19.8%), and placebo (18.8%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:\u2002<\/jats:bold>\n                    Bilastine 20\u2003mg once daily was efficacious, safe and not different from desloratadine 5\u2003mg once daily in the treatment of SAR symptoms.\n                  <\/jats:p>","DOI":"10.1111\/j.1398-9995.2008.01813.x","type":"journal-article","created":{"date-parts":[[2008,12,22]],"date-time":"2008-12-22T00:45:19Z","timestamp":1229906719000},"page":"158-165","source":"Crossref","is-referenced-by-count":101,"title":["Comparison of the efficacy and safety of bilastine 20\u2003mg\n                    <i>vs<\/i>\n                    desloratadine 5\u2003mg in seasonal allergic rhinitis patients"],"prefix":"10.1111","volume":"64","author":[{"given":"C.","family":"Bachert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sanquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Gorina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Van De Heyning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Loureiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Bilastine International Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,12,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.118891"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00013904"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01054.x"},{"key":"e_1_2_6_5_2","volume-title":"The Allergy Report","author":"Task Force on Allergic Disorders"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01057.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125003053"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200422060-00002"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.115569"},{"key":"e_1_2_6_10_2","first-page":"694","article-title":"The burden of rhinitis: nothing to sniff at","volume":"169","author":"Weir E","year":"2003","journal-title":"CMAJ"},{"key":"e_1_2_6_11_2","first-page":"925","article-title":"From allergic rhinitis to sinus diseases (sinusitis\/nasal polyps): epidemiologic and experimental links","volume":"17","author":"Demoly P","year":"2000","journal-title":"Rev Mal Respir"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.106150"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62612-9"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2002.1r3542.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp044141"},{"key":"e_1_2_6_16_2","first-page":"1","article-title":"Current trends in allergic reactions: a multidisciplinary approach to patient management","volume":"5","author":"Gelfand EW","year":"2003","journal-title":"Interdisciplinary Med"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2000.00526.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200506060-00005"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200607040-00002"},{"issue":"9","key":"e_1_2_6_20_2","first-page":"1198","article-title":"Relationship of dose to inhibition of wheal and flare for 5 doses of bilastine and 10\u2003mg cetirizine","volume":"47","author":"Sologuren A","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"e_1_2_6_21_2","first-page":"114","article-title":"In vitro hepatic metabolism of [14C] bilastine","volume":"39","author":"Lucero ML","year":"2007","journal-title":"Drug Metabol Rev"},{"key":"e_1_2_6_22_2","volume-title":"Bilastine, Investigational Drug Brochure version 8.0, July 2007","author":"FAES FARMA S.A."},{"issue":"1","key":"e_1_2_6_23_2","article-title":"Crossover, randomised, double\u2010blind, double\u2010dummy, placebo and positive standard\u2010controlled trial to assess the possible interaction on CNS effects between bilastine 20 mg and 80 mg) and alcohol (0.8 g\/kg) after single simultaneous administration in healthy subjects","volume":"99","author":"Garcia\u2010Gea C","year":"2006","journal-title":"Pharmacol Toxicol"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1991.tb00807.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)90000-2"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2000.00914.x"},{"issue":"1","key":"e_1_2_6_27_2","article-title":"The pharmacokinetics of bilastine after single and 14 days once daily administration","volume":"101","author":"Crean C","year":"2007","journal-title":"Basin Clin Pharmacol Toxicol"},{"issue":"88","key":"e_1_2_6_28_2","article-title":"Lack of significant effect of bilastine on ventricular repolarization. A thorough QT\/QTc study","volume":"63","author":"Sologuren A","year":"2008","journal-title":"Allergy"},{"issue":"1","key":"e_1_2_6_29_2","first-page":"383","article-title":"Efficacy and tolerability of once\u2010daily 5mg desloratadine, an H1 antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons","volume":"104","author":"Meltzer EO","year":"2001","journal-title":"Clin Drug Invest"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200222002-00005"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666180-00004"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565030-00004"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2004.00254.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2001.00101.x"},{"issue":"83","key":"e_1_2_6_35_2","article-title":"A phase 3 study comparing the efficacy and safety of once daily bilastine with cetirizine and placebo for the treatment of seasonal allergic rhinitis","volume":"62","author":"Kuna P","year":"2007","journal-title":"Allergy"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.2008.01813.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.2008.01813.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T14:02:40Z","timestamp":1696946560000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2008.01813.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,23]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1398-9995.2008.01813.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.2008.01813.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,23]]}}}